Sood AK - Search Results

1

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.

Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Yang D, et al. Among authors: sood ak. Cancer Cell. 2013 Feb 11;23(2):186-99. doi: 10.1016/j.ccr.2012.12.020. Cancer Cell. 2013. PMID: 23410973 Free PMC article.

2

p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.

Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. Sood AK, et al. Cancer Biol Ther. 2002 Sep-Oct;1(5):511-7. doi: 10.4161/cbt.1.5.167. Cancer Biol Ther. 2002. PMID: 12496479

3

The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.

Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. Sood AK, et al. Cancer Biol Ther. 2002 Nov-Dec;1(6):661-4. doi: 10.4161/cbt.316. Cancer Biol Ther. 2002. PMID: 12642690

4

EphA2 expression is associated with aggressive features in ovarian carcinoma.

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2004 Aug 1;10(15):5145-50. doi: 10.1158/1078-0432.CCR-03-0589. Clin Cancer Res. 2004. PMID: 15297418

5

Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.

Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Sood AK, et al. Am J Pathol. 2004 Oct;165(4):1087-95. doi: 10.1016/S0002-9440(10)63370-6. Am J Pathol. 2004. PMID: 15466376 Free PMC article.

6

Genomic instability is associated with lack of telomerase activation in ovarian cancer.

Landen CN, Klingelhutz A, Coffin JE, Sorosky JI, Sood AK. Landen CN, et al. Among authors: sood ak. Cancer Biol Ther. 2004 Dec;3(12):1250-3. doi: 10.4161/cbt.3.12.1235. Epub 2004 Dec 14. Cancer Biol Ther. 2004. PMID: 15477760

7

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2005 Jul 1;11(13):4923-33. doi: 10.1158/1078-0432.CCR-04-2060. Clin Cancer Res. 2005. PMID: 16000591

8

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Landen CN Jr, et al. Among authors: sood ak. Cancer Res. 2005 Aug 1;65(15):6910-8. doi: 10.1158/0008-5472.CAN-05-0530. Cancer Res. 2005. PMID: 16061675

9

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Bonome T, et al. Among authors: sood ak. Cancer Res. 2005 Nov 15;65(22):10602-12. doi: 10.1158/0008-5472.CAN-05-2240. Cancer Res. 2005. PMID: 16288054

10

EphA2 as a target for ovarian cancer therapy.

Landen CN, Kinch MS, Sood AK. Landen CN, et al. Among authors: sood ak. Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. doi: 10.1517/14728222.9.6.1179. Expert Opin Ther Targets. 2005. PMID: 16300469 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,140 results

Search Page